文献速递急性肾损伤遗传性与小管间质肾病

癌症免疫治疗的肾毒性:过去、现在与未来

Nephrotoxicity of Cancer Immunotherapies: Past, Present and Future.
PubMed 文献 · J Am Soc Nephrol · 2018-06-29

本文综述癌症免疫治疗相关肾毒性的演变与认识。干扰素与高剂量白细胞介素-2 为较早期的免疫治疗,近十年出现的免疫检查点抑制剂与嵌合抗原受体 T 细胞(CAR-T)提供了更有效的治疗选择,但与其他抗癌药物一样可导致免疫相关不良事件,包括肾毒性。

要点

  • 免疫检查点抑制剂与 CAR-T 等新型免疫治疗可引发免疫相关不良事件,肾毒性是其中之一。
  • 干扰素与高剂量 IL-2 等早期免疫治疗同样需关注肾脏不良反应。
  • 肿瘤肾脏病学(onco-nephrology)已作为交叉亚专科出现,提示抗癌治疗肾损伤在临床中日益常见。

核心结论

  • 癌症免疫治疗与其他抗癌治疗一样与免疫相关不良事件相关,其中包括肾毒性,需在肿瘤肾脏病学框架下识别与管理。

研究设计与样本

  • 综述性文章,回顾癌症免疫治疗(干扰素、高剂量 IL-2、免疫检查点抑制剂、CAR-T)相关肾毒性的过去、现在与未来,未报告检索范围与样本量。

主要发现

  • 传统化疗药物与靶向特定基因/蛋白的新型药物虽有效,但存在多种不良肾脏效应。
  • 免疫治疗通过增强免疫系统对肿瘤细胞的识别与靶向发挥作用,是根除肿瘤的重要方式。
  • 免疫检查点抑制剂是癌症免疫治疗领域的新增手段,CAR-T 用于多种血液系统恶性肿瘤。
  • 免疫治疗与其他抗癌药物一样伴随免疫相关不良事件,包括肾毒性。

临床怎么用

  • 临床面对接受免疫检查点抑制剂、CAR-T、干扰素或高剂量 IL-2 的肿瘤患者时,应将肾毒性纳入免疫相关不良事件的评估范围。

局限性

  • 本文为综述,摘要未报告具体肾毒性发生率、诊断标准、阈值或处理剂量等定量数据。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Nephrotoxicity from cancer therapies is common and increasingly encountered in clinical practice, such that the subfield of "onco-nephrology" has emerged. Conventional chemotherapeutic drugs and novel agents targeting specific genes/proteins are effective cancer therapies but suffer from a number of adverse kidney effects. An effective avenue of cancer treatment is immunotherapy, which uses drugs that augment immune system-mediated recognition and targeting of tumor cells. As such, leveraging the immune system to target malignant cells represents an important modality in eradicating cancer. IFN and high-dose IL-2 are older immunotherapies used in clinical practice to treat various malignancies, whereas new cancer immunotherapies have emerged over the past decade that offer even more effective treatment options. The immune checkpoint inhibitors are an exciting addition to the cancer immunotherapy armamentarium. Chimeric antigen receptor T cells are also a new immunotherapy used to treat various hematologic malignancies. However, as with the conventional and targeted cancer agents, the immunotherapies are also associated with immune-related adverse effects, which includes nephrotoxicity.

来源:J Am Soc Nephrol,查看原文。版权归原作者所有。

引用

  1. Perazella MA, Shirali AC. Nephrotoxicity of Cancer Immunotherapies: Past, Present and Future. J Am Soc Nephrol. 2018. PMID: 29959196. doi:10.1681/ASN.2018050488

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。